natgillin/translations-raw huggingface dataset:
In other studies or in post-marketing experience, rare cases of intracranial / intracerebral and retroperitoneal bleedings have been reported.
V drugih preskušanjih ali v postmarketinškem obdobju so poročali o redkih primerih intrakranialne/intracerebralne in retroperitonealne krvavitve.
Of the patients treated with a thrombolytic, 84% were treated with a non-fibrin specific agent (primarily streptokinase).
84 % s trombolitikom zdravljenjih bolnikov se je zdravilo s fibrinsko nespecifičnim zdravilom (predvsem streptokinazo).
(2) Npn stands for non-protein-nitrogen such as urea, uric acid, amino acid, etc.
(2) Npn pomeni neproteinski dušik, kot na primer sečnina, sečna kislina, aminokisline, ipd.
1: Odds ratio: Low Dose/Standard Dose Note: MI - myocardial infarction.
1: Razmerje obetov: nizek odmerek/standardni odmerek Opomba: MI - miokardni infarkt.
Only fondaparinux can be used to calibrate the anti-Xa assay (the international standards of heparin or LMWH are not appropriate for this use).
Za kalibracijo testa anti-Xa se lahko uporabi samo fondaparinuks (mednarodni standardi heparina ali LMWH za ta namen niso primerni).
Neutralisation of Factor Xa interrupts the blood coagulation cascade and inhibits both thrombin formation and thrombus development.
Nevtralizacija faktorja Xa prekine kaskado strjevanja krvi in zavre tako tvorbo trombina kot razvoj trombusa.
Rare: hypokalaemia
Redki: hipokaliemija
Do not administer intramuscularly.
Ne injicirajte ga intramuskularno.
Therefore the physician should determine if the benefit of treatment outweighs the risk (see sections 4.2 and 4.3).
Zdravnik mora zato presoditi, če korist zdravljenja upravičuje morebitno tveganje (glejte poglavji 4.2 in 4.3).
This study included acutely ill medical patients, aged ≥ 60 years, expected to require bed rest for at least four days, and hospitalized for congestive heart failure NYHA class III/IV and/or acute respiratory illness and/or acute infectious or inflammatory disease.
V to študijo so vključili akutno bolne internistične bolnike, stare ≥ 60 let, za katere so pričakovali, da bodo morali ležati vsaj 4 dni dolgo, hospitalizirani pa so bili zaradi kongestivnega popuščanja srca razreda III/IV po NYHA in/ali akutne respiracijske bolezni in/ali akutne infekcijske ali vnetne bolezni.
Aspen Notre Dame de Bondeville 1, rue de l'Abbaye F-76960 Notre Dame de Bondeville France
Aspen Notre Dame de Bondeville 1 rue de l'Abbaye 76960 Notre Dame de Bondeville Francija
Race - Pharmacokinetic differences due to race have not been studied prospectively.
Rasa - Prospektivno farmakokinetičnih razlik med rasami niso raziskovali.
A pilot dose-finding and pharmacokinetic study of fondaparinux in children with deep vein thrombosis
Pilotna študija določitve odmerka in farmakokinetike fondaparinuksa pri otrocih z globoko vensko trombozo
Fondaparinux is administered by deep subcutaneous injection while the patient is lying down.
Fondaparinuks se injicira globoko pod kožo, medtem ko bolnik leži.
Fondaparinux does not bind significantly to other plasma proteins, including platelet factor 4 (PF4).
Fondaparinuks se ne veže pomembno na druge proteine plazme, vključno s faktorjem 4 (PF4).
Randomised patients could have been pre-treated with UFH during the screening phase but patients treated for more than 24 hours with therapeutic dose of anticoagulant or with uncontrolled hypertension were excluded.
Randomizirani bolniki so smeli biti predhodno zdravljeni z UFH med presejalno fazo, bolnike, ki so bili več kot 24 ur zdravljeni s terapevtskim odmerkom antikoagulantnega sredstva, in tiste z neobvladano hipertenzijo, pa so izključili.
Plasma concentrations of half the mean Cmax values are reached 25 minutes post-dosing.
Polovična vrednost povprečne vrednosti Cmax v plazmi je dosežena v 25 minutah po odmerjanju.
If you forget to take Arixtra
Če ste pozabili uporabiti zdravilo Arixtra
Consequently, unbound concentrations of fondaparinux are expected to be unchanged in patients with mild to moderate hepatic impairment, and therefore, no dose adjustment is necessary based on pharmacokinetics.
Posledično pričakujemo, da se pri bolnikih z blago do zmerno okvaro jeter koncentracije prostega fondaparinuksa ne bodo spremenile in na osnovi farmakokinetike odmerka torej ni treba prilagajati.
A total of 2,184 patients were treated; for both groups, patients were treated for at least 5 days and up to 22 days (mean 7 days).
Zdravili so vsega skupaj 2.184 bolnikov; bolnike iz obeh skupin so zdravili vsaj po 5 dni in do 22 dni dolgo (povprečno po 7 dni).
Other antiplatelet medicinal products (acetylsalicylic acid, dipyridamole, sulfinpyrazone, ticlopidine or clopidogrel), and NSAIDs should be used with caution.
Druga antitrombotična zdravila (acetilsalicilna kislina, dipiridamol, sulfinpirazon, tiklopidin ali klopidogrel) in NSAID moramo uporabljati previdno.
As for other anticoagulants, fondaparinux should be used with caution in patients who have undergone recent surgery (<3 days) and only once surgical haemostasis has been established.
Tako kot velja za druga antikoagulantna sredstva, je treba fondaparinuks previdno uporabljati pri bolnikih, ki so pred nedavnim (< 3 dni) imeli operacijo, to pa šele po tistem, ko vzpostavimo kirurško hemostazo.
OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
C. DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET Z ZDRAVILOM
The elderly population is at increased risk of bleeding.
Pri skupini starejših bolnikov je povečano tveganje za krvavitve.
Excipient(s) with known effect: Contains less than 1 mmol of sodium (23 mg) per dose, and therefore is essentially sodium free.
Pomožne snovi z znanim učinkom: vsebuje manj kot 1 mmol natrija (23 mg) na odmerek, kar v bistvu pomeni brez natrija.
All patients received standard medical treatment for UA/NSTEMI, with 34% of patients undergoing PCI and 9% undergoing CABG.
Vsi bolniki so bili standardno zdravljeni za UA/NSTEMI, PCI je bila izvedena pri 34 % bolnikov, CABG pa pri 9 % bolnikov.
The study population was 64% female, with a median age of 58 years, 4.4% had a creatinine clearance <50ml/min.
V študijski populaciji je bilo 64 % žensk, mediana starost je bila 58 let in 4,4 % je imelo očistek kreatinina < 50 ml/min.
Elimination of fondaparinux decreases with weight.
Izločanje fondaparinuksa se zmanjšuje s telesno maso.
• pain and swelling at injection site
• bolečina in oteklina na mestu injiciranja;
The majority of endpoint events were diagnosed by a prescheduled venography and consisted mainly of distal DVT, but the incidence of proximal DVT was also significantly reduced.
Večino končnih dogodkov so diagnosticirali z vnaprej načrtovano venografijo in so obsegali pretežno distalno globoko vensko trombozo (DVT), vendar je bila tudi pogostnost proksimalne globoke venske tromboze (DVT) pomembno zmanjšana.
• treat blood clots in blood vessels that are near the surface of the skin of the legs (superficialvein thrombosis).
• zdravljenje krvnih strdkov v žilah, ki potekajo blizu površine kože na nogah (povrhnja venska tromboza).
Fondaparinux may be restarted at least 6 hours post-operatively provided haemostasis has been achieved.
Fondaparinuks je mogoče znova začeti uporabljati najmanj 6 ur po operaciji, če je dosežena hemostaza.
In vitro, fondaparinux is highly and specifically bound to antithrombin protein with a dose-dependant plasma concentration binding (98.6% to 97.0% in the concentration range from 0.5 to 2 mg/l).
In vitro se fondaparinuks v veliki meri in specifično veže na antitrombinski protein z deležem vezave, ki je v smislu odvisnosti od odmerka odvisna od koncentracije v plazmi (98,6 % do 97,0 % v razponu koncentracije od 0,5 do 2 mg/l).
The lower plasma concentrations of fondaparinux were attributed to reduced binding to ATIII secondary to the lower ATIII plasma concentrations in subjects with hepatic impairment thereby resulting in increased renal clearance of fondaparinux.
Nižje koncentracije fondaparinuksa v plazmi so pripisali manjši vezavi na ATIII zaradi nižjih koncentracij ATIII v plazmi pri osebah z okvaro jeter in zaradi tega večjemu ledvičnemu očistku fondaparinuksa.
Experience shows that in patients undergoing hip fracture surgery, the risk of VTE continues beyond 9 days after surgery.
Izkušnje kažejo, da traja pri bolnikih po operaciji zloma kolka tveganje za VTE več kot 9 dni po operaciji.
The initial dose should be given 6 hours following surgical closure provided that haemostasis has been established.
Začetni odmerek se mora dati 6 ur po zaključku operacije pod pogojem, da je dosežena hemostaza.
A treatment duration of 6-14 days has been clinically studied in medical patients (see section 5.1).
Zdravljenje bolnikov v trajanju od 6-14 dni je bilo klinično preučeno (glejte poglavje 5.1).
These are patients with refractory or recurrent angina associated with dynamic ST deviation, heart failure, lifethreatening arrhythmias or haemodynamic instability.
To so bolniki z neodzivno ali ponavljajočo se angino pektoris, povezano z dinamično deviacijo segmenta ST, s srčnim popuščanjem, z življenjsko nevarnimi srčnimi aritmijami ali s hemodinamsko nestabilnostjo.
This medicinal product contains less than 23 mg of sodium in each dose and therefore is essentially sodium-free.
To zdravilo vsebuje manj kot 23 mg natrija na odmerek, kar v bistvu pomeni brez natrija.
If you are pregnant, or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Če ste noseči ali dojite, menite, da bi lahko bil noseči ali načrtujete zanositev, se posvetujte s svojim zdravnikom ali s farmacevtom, preden vzamete to zdravilo.
In a study of 3235 high-risk UA/NSTEMI patients scheduled for angiography and treated with openlabel fondaparinux (OASIS 8/FUTURA), the 2026 patients indicated for PCI were randomised to receive one of two double-blind dose regimens of adjunctive UFH.
V študiji 3.235 bolnikov z UA/NSTEMI z velikim tveganjem, predvidenih za angiografijo, ki so v odprtem delu študije prejemali fondaparinuks (OASIS 8/FUTURA), so 2.026 bolnikov, indiciranih za PCI, randomizirali na prejemanje ene od dveh dvojno slepih shem dodatnega UFH.
Patients were randomised to receive fondaparinux 2.5 mg once daily or placebo for 45 days in addition to elastic stockings, analgesic and/or topical NSAIDS anti-inflammatory drugs.
Bolniki so bili za 45 dni randomizirani na prejemanje 2,5 mg fondaparinuksa enkrat na dan ali placeba, dodatno poleg elastičnih nogavic, analgetikov in/ali lokalnih nesteroidnih protivnetnih zdravil.
If you stop the treatment before your doctor told you to, you are at risk of developing a blood clot in a vein of your leg or lung.
Če prenehate uporabljati zdravilo prej, kot vam je predpisal zdravnik, ste v nevarnosti, da se vam v venah nog ali pljuč razvije krvni strdek.
Randomised patients received either “low dose” UFH regimen (50 U/kg irrespective of planned GPIIb/IIIa use; non ACT guided) or “standard dose” UFH regimen (no GPIIb/IIIa use: 85 U/kg, ACT guided; planned GPIIb/IIIa use: 60 U/kg, ACT guided) immediately prior to the start of the PCI.
Randomizirani bolniki so prejemali bodisi shemo z "nizkim odmerkom" UFH (50 e./kg ne glede na načrtovano uporabo GPIIb/IIIa; ne po ACT) bodisi shemo s "standardnim odmerkom" UFH (brez uporabe GPIIb/IIIa: 85 e./kg, po ACT; načrtovana uporaba GPIIb/IIIa: 60 e./kg, po ACT)
Clean the injection area with an alcohol wipe.
Mesto injiciranja očistite z zložencem, namočenim v alkoholu.
The majority (70/80) of the recorded VTE events were venographically detected non-symptomatic cases of DVT.
Večina (70/80) zabeleženih VTE dogodkov je bila venografsko odkritih primerov asimptomatske globoke venske tromboze (DVT).
Paediatric patients - Limited data are available in paediatric patients (see section 5.1).
Pediatrični bolniki - Podatki za pediatrične bolnike so omejeni (glejte poglavje 5.1).
What Arixtra is and what it is used for What you need to know before you use Arixtra How to use Arixtra
Kaj je zdravilo Arixtra in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo Arixtra Kako uporabljati zdravilo Arixtra Možni neželeni učinki
The primary adjudicated endpoint was a composite of death, myocardial infarction (MI) and refractory ischaemia (RI) within 9 days of randomisation.
Primarni vrednoteni opazovani dogodek je bil sestavljen iz smrtnega izida, miokardnega infarkta (MI) in refrakterne ishemije (RI) v 9 dneh po randomizaciji.
In patients receiving fondaparinux for treatment of VTE rather than prophylaxis, spinal/epidural anaesthesia in case of surgical procedures should not be used.
Pri bolnikih, ki dobivajo fondaparinuks za zdravljenje VTE, ne za profilakso, uporaba spinalne/epiduralne anestezije v primeru kirurških postopkov ni dovoljena.
Fondaparinux also provided a significant reduction in the rate of symptomatic VTE (DVT, and / or PE) [1 (0.3%) vs 9 (2.7%) patients, respectively] including two fatal PE reported in the placebo group.
Fondaparinuks je prav tako omogočil pomembno zmanjšanje deleža simptomatskih venskih trombemboličnih dogodkov (DVT, in / ali PE) [1 (0,3 %) vs 9 (2,7 %) bolnikov] vključno z dvema primeroma PE s smrtnim izidom, o katerih so poročali v skupini s placebom.
At the end of this period, 656 patients were randomised to receive fondaparinux 2.5 mg once daily or placebo for an additional 21 +/- 2 days.
Na koncu tega obdobja, so 656 bolnikov naključno razporedili v skupini, ki sta prejemali 2,5 mg fondaparinuksa enkrat na dan ali placebo, še dodatnih 21 +/- 2 dni.
The fondaparinux clinical program in treatment of Venous Thromboembolism was designed to demonstrate the efficacy of fondaparinux for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE).
Klinični program za fondaparinuks pri zdravljenju venske trombembolije je bil oblikovan, da bi dokazal učinkovitost fondaparinuksa za zdravljenje globoke venske tromboze (DVT) in pljučne embolije (PE).
The safety of fondaparinux has been evaluated in 2,517 patients treated for Venous ThromboEmbolism and treated with fondaparinux for an average of 7 days.
Varnost fondaparinuksa so ovrednotili pri 2.517 bolnikih, zdravljenih zaradi venske trombembolije s fondaparinuksom, povprečno 7 dni dolgo.
Concomitant oral anticoagulation treatment should be initiated as soon as possible and usually within 72 hours.
Čimprej, navadno pa v prvih 72 urah, je treba uvesti sočasno peroralno antikoagulantno zdravljenje.
• anaemia (a reduction in the number of red blood cells).
• anemija (zmanjšanje števila rdečih krvnih celic).
How to use Arixtra
Kako uporabljati zdravilo Arixtra
Treatment of patients with acute symptomatic spontaneous superficial-vein thrombosis without concomitant Deep-Vein Thrombosis (DVT)
Zdravljenje bolnikov z akutno simptomatsko spontano povrhnjo vensko trombozo brez sočasne globoke venske tromboze (DVT)
All enrolled patients received fondaparinux 2.5 mg subcutaneously, once daily for up to 8 days, or until hospital discharge.
Vsi vključeni bolniki so prejemali 2,5 mg fondaparinuksa subkutano enkrat na dan do 8 dni oz. do odpusta iz bolnišnice.
Rare: other bleeding (hepatic, retroperitoneal, intracranial/intracerebral), thrombocythaemia
Redki: druge krvavitve (hepatične, retroperitonealne, intrakranialne/intracerebralne), trombocitemija
Similarly, in UA/NSTEMI patients with life threatening conditions that require urgent revascularisation, the use of fondaparinux prior to and during PCI is not recommended.
Tudi pri ogroženih bolnikih z UA/NSTEMI, ki zahtevata urgentno revaskularizacijo, uporabe fondaparinuksa pred in med PCI ne priporočamo.
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT DRUGI PODATKI
• leg pain or stomach pain
• bolečine v nogah ali trebuhu;
Follow-up therapy with another anticoagulant medicinal product If follow-up treatment is to be initiated with heparin or LMWH, the first injection should, as a general rule, be given one day after the last fondaparinux injection.
Če moramo nadaljevanje zdravljenja začeti s heparinom ali LMWH, je splošno pravilo, da se daje prvo injekcijo zdravila en dan po zadnji injekciji fondaparinuksa.
Arixtra is used to treat adults with a blood clot in the blood vessels of their legs (deep vein thrombosis) and/or lungs (pulmonary embolism).
Zdravilo Arixtra se uporablja za zdravljenje odraslih s krvnimi strdki v žilah nog (globoka venska tromboza) in/ali pljuč (pljučna embolija).
• It is normal to see a small air bubble in this syringe.
• Prisotnost majhnega zračnega mehurčka v injekcijski brizgi je normalna.
Prevention of Venous Thromboembolic Events (VTE) in adult medical patients who are judged to be at high risk for VTE and who are immobilised due to acute illness such as cardiac insufficiency and/or acute respiratory disorders, and/or acute infectious or inflammatory disease.
Preprečevanje venskih trombemboličnih dogodkov (VTE) pri odraslih internističnih bolnikih, za katere sodimo, da pri njih obstaja velika nevarnost VTE in ki so imobilizirani zaradi akutne bolezni, na primer srčne insuficience in/ali akutnih respiracijskih bolezni in/ali akutnih okužb ali vnetnih bolezni.
Tell your doctor if you are allergic to latex before being treated with Arixtra.
→ Svojemu zdravniku morate pred začetkom zdravljenja z zdravilom Arixtra povedati, če ste alergični na lateks.
• if you are allergic to fondaparinux sodium or to any of the other ingredients of this medicine
• če ste alergični na natrijev fondaparinuksat ali katerokoli sestavino tega zdravila (navedeno v poglavju 6),
The associated 5th and 95th percentiles are, respectively, 0.97 and 1.92 for Cmax (mg/l), and 0.24 and 0.95 for Cmin (mg/l).
Ustrezna 5. in 95. percentil sta 0,97 in 1,92 za Cmax (mg/l) in 0,24 in 0,95 za Cmin (mg/l).
At the 10 mg dose used in interaction studies, fondaparinux did not significantly influence the anticoagulation activity (INR) of warfarin.
Pri 10-miligramskem odmerku, ki so ga uporabljali v študijah medsebojnega delovanja, fondaparinuks ni pomembno vplival na antikoagulacijsko aktivnost (INR) varfarina.
Twelve (0.37%) enrolled patients experienced thrombus in the arterial sheath, of these 7 were reported during angiography and 5 were reported during PCI.
Dvanajstim (0,37 %) vključenim bolnikom se je pojavil tromb v arterijski ovojnici katetra; od tega je bilo 7 primerov opisanih med angiografijo in 5 med PCI.
• Subcutaneous administration
• Subkutana uporaba
Incidences of bleeding events in patients receiving the recommended regimen in the treatment of DVT or PE and aged <65 years, 65-75 and >75 years were 3.0 %, 4.5 % and 6.5 %, respectively.
Incidence krvavitev pri bolnikih na priporočeni shemi zdravljenja DVT ali PE in starih < 65 let, 65-75 let oziroma > 75 let so bile 3,0 %, 4,5 % oziroma 6,5 %.
These agents include desirudin, fibrinolytic agents, GP IIb/IIIa receptor antagonists, heparin, heparinoids, or Low Molecular Weight Heparin (LMWH).
Med te učinkovine spadajo dezirudin, fibrinolitične učinkovine, antagonisti receptorjev GP IIb/IIIa, heparin, heparinoidi ali nizkomolekularni heparin (LMWH).
Fondaparinux is a synthetic and selective inhibitor of activated Factor X (Xa).
Fondaparinuks je sintetični in selektivni zaviralec aktiviranega faktorja X (Xa).
The corresponding incidences in patients receiving the recommended regimen of enoxaparin in the treatment of DVT were 2.5%, 3.6% and 8.3% respectively, while the incidences in patients receiving the recommended regimen of UFH in the treatment of PE were 5.5%, 6.6% and 7.4%, respectively.
Ustrezne incidence pri bolnikih, ki so prejemali priporočeno shemo enoksaparina za zdravljenje DVT, so bile 2,5 %, 3,6 % oziroma 8,3 %, medtem ko so bile incidence pri bolnikih na priporočeni shemi UFH za zdravljenje PE, 5,5 %, 6,6 % oziroma 7,4 %.
The mean treatment duration was 6.2 days on fondaparinux.
Zdravljenje s fondaparinuksom je v povprečju trajalo 6,2 dni.
Therefore adjunctive UFH should be used during non-primary PCI according to standard practice (see posology in section 4.2).
Zato je treba med neprimarno PCI uporabiti dodatni nefrakcionirani heparin v skladu s standardno prakso (glejte Odmerjanje v poglavju 4.2).
Rare: allergic reaction (including very rare reports of angioedema, anaphylactoid/anaphylactic reaction)
Redki: alergijska reakcija (vključno z zelo redkimi poročili o angioedemu, anafilaktoidni/anafilaktični reakciji)
In STEMI patients undergoing primary PCI, the use of fondaparinux prior to and during PCI is not recommended.
Pri bolnikih s STEMI, pri katerih bo opravljena primarna PCI, uporabe fondaparinuksa pred in med PCI ne priporočamo.
One type of syringe has an automatic needle protection system and the other type has a manual needle protection system.
Ena vrsta injekcijskih brizg ima samodejni, druga pa ročni sistem za zaščito igle.
PHARMACEUTICAL FORM AND CONTENTS Solution for injection, 2 pre-filled syringes with an automatic safety system Solution for injection, 7 pre-filled syringes with an automatic safety system Solution for injection, 10 pre-filled syringes with an automatic safety system Solution for injection, 20 pre-filled syringes with an automatic safety system Solution for injection, 2 pre-filled syringes with a manual safety system Solution for injection, 10 pre-filled syringes with a manual safety system Solution for injection, 20 pre-filled syringes with a manual safety system
Raztopina za injiciranje, 2 napolnjeni injekcijski brizgi s samodejnim varnostnim sistemom Raztopina za injiciranje, 7 napolnjenih injekcijskih brizg s samodejnim varnostnim sistemom Raztopina za injiciranje, 10 napolnjenih injekcijskih brizg s samodejnim varnostnim sistemom Raztopina za injiciranje, 20 napolnjenih injekcijskih brizg s samodejnim varnostnim sistemom
Treatment of ST segment elevation myocardial infarction (STEMI) OASIS 6 was a double blind, randomised study assessing the safety and efficacy of fondaparinux 2.5 mg once daily, versus usual care (placebo (47%) or UFH (53%) in approximately 12,000 patients with STEMI.
OASIS 6 je bila dvojno slepa, randomizirana študija, ki je vrednotila varnost in učinkovitost fondaparinuksa v odmerku 2,5 mg enkrat na dan v primerjavi z običajnim zdravljenjem (placebo (47 %) ali UFH (53 %)) pri približno 12.000 bolnikih s STEMI.
Fondaparinux must not be administered intramuscularly.
Fondaparinuksa se ne sme injicirati intramuskularno.
Gender - No gender differences were observed after adjustment for body weight.
Spol - Po izenačenju glede na telesno maso razlik med spoloma niso opazili.
Animal studies are insufficient with respect to effects on pregnancy, embryo/foetal development, parturition and postnatal development because of limited exposure.
Zaradi omejene izpostavljenosti izsledki študij na živalih o vplivu na nosečnost, embrio-fetalni razvoj, porod in postnatalni razvoj niso zadostni.
• allergic reaction (including itching, swelling, rash)
• alergijska reakcija (vključno s srbenjem, oteklostjo, izpuščajem);
• Store below 25°C.
• Shranjujte pod 25°C.
Patients could be recommended to self-inject the product when they are judged willing and able to do so. Physicians should provide clear instructions for self-injection.
Bolnikom se lahko svetuje, da si sami injicirajo zdravilo, če se presodi, da so pripravljeni in sposobni za to.
• wound infection
• okužba rane;
Important note
Pomembna opomba
Do not try to remove this air bubble before making the injection - you may lose some of the medicine if you do.
Pred injiciranjem zračnega mehurčka ne poskušajte odstraniti, ker lahko pri tem izgubite tudi nekaj zdravila.
ATC code: B01AX05
Farmakoterapevtska skupina: Antitrombotiki Oznaka ATC: B01AX05
• prevent the formation of blood clots during and shortly after a period of restricted mobility due to acute illness
• preprečevanje nastajanja krvnih strdkov med obdobjem in po obdobju omejene gibljivosti